SUBJECT INDEX

A

ACE inhibitors, 8–16, 322, 327, 332
  captopril, 8–14
  enalapril, 14
  fosinopril, 14
  lysinopril, 14
  zofenopril, 14
Acetylcholine, 227
Acetylcholinesterase (AChE), 226, 281–83, 285–98, 306–12
  alternate mRNA processing in, 281–83, 285–88
  catalytic mechanisms, 295–98
    substrate inhibition and activation, 297–98
  molecular species of, 285–88
  site-specific mutagenesis analyses, 306–12
  three-dimensional structure of, 288–95
    bis-quaternary ligands and, 294–95
    catalytic triad, 289–90
    crystallographic analysis, 288–95
    folding patterns, 288–89
    ligand specificity, 293–94, 311–12
    modeling, 289
    peripheral anionic site, 290–93
  (See also Butylcholinesterase, Cholinesterases, Serine hydrolase)
Actinomycin D, 198, 203
Acute bovine pulmonary edema and emphysema (ABPE), 91–93
Adducts
  AFB-N^7-guanine
    aflatoxin exposure biomarker, 138–39, 153, 162
  DNA, 41–60, 153–54, 162–63
    aflatoxin B_1 and, 153–54, 162–63
  macromolecular, 41–60, 99–111
    3-methylindole toxicity and, 99–111
  3-methylindole-glutathione, 100
  protein, 46–48, 60
    albumin, 46–48
    alkyl, 60
    hemoglobin, 46–48, 60
α_1-Adrenergic receptor subtypes, 117–30
  blood pressure and, 118
  molecular cloning of, 119–22
  muscle growth and, 118
  nasal congestion and, 118
  pharmacological characterization of, 118–19
  prostate function and, 118
  signal transduction mechanisms
    calcium channel and, 127–29
  smooth muscle function and, 118
  subtype-selective drugs, 125–27
    benoxathian, 125
    methoxamine, 126–27
    5-methylurapidil, 125
    (+)niguldipine, 125
    phentololamine, 125
    phenylephrine, 126
    prazobind, 126
    prazosine, 126
    oxymetazoline, 125–27
    spiperone, 126
    WB 4101, 125
α_2-Adrenergic receptor subtypes, 117
β-Adrenergic receptor subtypes, 117
Adrenergic receptors, 117–30
  therapeutic targets, 117
Adriamycin, 203, 206
AFB-N^7-guanine, 138–39, 153
Aflatoxins, 135–63
  biotransformation of, 139–53
    conjugation , 149–51
    CYP450 isoenzymes and, 144–48
    hydroxylation and O-demethylation, 143–44
    glucuronidation and sulfation of hydroxylate metabolites, 151
    microsomal oxidation of AFB_1, 140
    modulation, 151–53
    reduction, 148–49
  carcinogenicity of, 135–63
    animal evidence of, 136–37
    human evidence of, 137–39
    risk assessment, 160–61
  dietary contamination from, 135–63
  genotoxic effects of, 153–54
  hepatotoxicity and, 135–36
  Kwashiorkor and, 135
  liver cancer and, 135–63
  mutations in the *p53* gene and, 156–60
  oncogene activation and, 155–56
  Reye's syndrome and, 135
  synergism with hepatitis B virus, 139, 159
  tumor suppression gene inactivation and, 155–56
Aflatoxin B_1
  dosimetry of carcinogenesis and, 53, 55–56
  hepatitis B virus and, 55–56
Ah receptor
  cytochrome P-450 isozyme induction and, 351–56
Airway reactivity
  epinephrine and, 117
  norepinephrine and, 117
Albumin adducts, 46–48, 60
Alkyl adducts, 60
Alternative mRNA processing
  acetylcholinesterase gene, 285–88
Alzheimer's disease
  β-amyloid plaques and, 69–83
  β-amyloid precursor protein and
    alterations in metabolism of, 75–76
    mutations in gene sequence of, 75
  autosomal dominant pattern of inheritance of, 75
  chromosome 14 and, 75
  chromosome 19 and, 75
  chromosome 21 and, 74–75
  Down's syndrome and, 72–75
  head trauma and, 75, 82
  neuritic plaques and, 70
  neurofibrillary tangles and, 70–73
  neuronal degeneration and, 69–72
  neuropil threads and, 70, 72
  pathogenesis of
    β-amyloid plaques and, 69, 72–76, 79–83
  therapy for, 69–72
    cholinergic deafferentation and, 72
    new targets for, 80–83
    proteinase and, 80–83
    tetrahydroaminoacridine, 72

γ-Aminobutyric acid (See GABA)
Aminopeptidase, 13
Amonafide, 203
m-AMSA, 203
β-Amyloid
  Alzheimer's disease and, 69–83
  Down's syndrome and, 72–75, 81–82
  gene structure of, 76–77
  genesis of, 78–81
    carboxy-terminal and, 79–81
    Golgi complex and, 79–80
  mechanisms of formation of, 81–83
  transcriptional features of, 77–78
β-Amyloid plaques
  Alzheimer's disease and pathogenesis of, 69–76, 79–83
  Down's syndrome and, 72–75, 81–82
  dystrophic neurites, 72–73
  mechanisms of formation of, 81–83
  neurofibrillary tangles and, 70–72
  neuronal cytoskeleton and, 72–73
  synaptic structure alterations in, 73
  transgenic mouse studies of, 74
β-Amyloid precursor protein
  Alzheimer's disease and, 75–83
  β-amyloid deposition and, 75–83
  gene encoding, 75
    chromosome 21 and, 75
  gene structure of, 76–77
  metabolism of, 76, 78–83
    alterations in, 76–83
    normal, 78
  secretase and, 78
  transcriptional features of, 77–78
Amyotrophic lateral sclerosis (ALS)
  altered glutamate transport and, 224
Anaphylatoxins, 19, 24–26, 29–30
  generation of, 24–26
  neutrophils and, 19, 24–26
Angiotensin, 6–8
Antibiotics
  β-lactam, 322, 327
  quinolone, 192
Anticancer drugs
DNA topoisomerases, 192–209
  actinomycin D, 198
  adriamycin, 203, 206
  amonafide, 203
  m-AMSA, 203
  batracyclin, 203
  bulgarein, 200
  camptothecin, 194–97, 203, 206–8
  chromomycin A3, 198
  ellipticine, 203
  etoposide (VP-16), 203
  groove binders, 197–200
  ICRF 194, 203
  [^{131}I]meta-iodobenzyl-guanidine, 224
  menadiones, 203
  mithramycin, 198
  nogalamycin, 198
  VM-26, 203, 207
Antidepressants
  fluoxetine, 224
  monoamine neurotransmitters and, 224
  serotonin-transport inhibitors, 224
Antiinflammatory agents, 2–3
  steroid, 3
Antioxidants
  glutathione, 99, 101–3, 111
  vitamin E, 99
Apolipoprotein E
  Alzheimer's disease risk and familial, 75
  chromosome 19 and, 75
Aromatic amines
  dosimetry of carcinogenesis and, 53
Arterial pressure
  vascular
    flow-dependent, 175–86
    (See also Vascular smooth muscle tone)

B

Baroreceptor buffer mechanism, 173–74
Batracyclin, 203
Benoxathian, 125
Benzo(a)pyrene-DNA adducts, 43
Biomarkers
  urinary
    AFB-N^7-guanine, 138–39
Biotransformation
  aflatoxin, 139–53
Blood pressure
  α_1-adrenergic receptor subtypes and, 118
Blood vessels, 173–86
  (See also Vascular smooth muscle tone)
Bothrops jararaca venom, 6
BPP5a, 6
Bradykinin, 2, 7, 15
  first antagonist of, 2
  synthesis of, 2
Bulgarein, 200
Butylcholinesterase (BuChE), 282–83, 285, 287–88, 306
  alternative mRNA processing in, 285–88
  site-specific mutagenesis analyses, 306–11
  (See also Acetylcholinesterase, Cholinesterases, Serine hydrolase)

C

Caerulein, 4
Calciton gene-related peptide (CGRP), 180
Calcitonin, 2
Calcium-activated neutral proteinase, 80
Calcium-activated serine proteinase, 80
Calcium channel
  α_1-adrenergic receptor subtypes and, 127–29
Camptothecin
  antitumor activity of, 194\97, 203, 206–8
Cancer
  liver
    aflatoxins and, 135–63
    hepatitis B virus and, 138–39, 159
Captopril, 8–14
Carcinogenesis
  aflatoxins and, 135–63
    DNA adducts formed with, 153–54
  chemical
    DNA adducts and, 42–46, 153–54
    TCDD, 343–64
  dosimetry of, 48–60
    aflatoxin B$_1$, 53, 55–56
    animal models for, 50–54
    aromatic amines, 52–53
    biologically effective dose, 49–50
    internal dose, 48–49
    N-nitrosamines, 50–52, 59–60
    polycyclic aromatic hydrocarbon, 52, 57–58
  hepatitis B virus and, 138–39
  macromolecular adducts, 41–60, 99–111

3-methylindole toxicity and, 99–111
nucleic acid binding and, 104–8
risk extrapolation, 53–54
TCDD-induced, 343–64
Ah receptor and, 345, 347–48, 351–52, 355
biochemical responses in, 352–57
cytochrome P-450 isozyme induction and, 353–56
epidemiological studies, 357–61
estrogen receptor and, 356–57
initiation of, 351–52
mechanisms of, 347–48, 349–51
risk assessment of, 348–49, 351
Carcinoma
hepatocellular
aflatoxin exposure and, 135–63
Cardiovascular function
epinephrine and, 117
norepinephrine and, 117
Cellular macromolecules
3-methylindole binding to, 100–11
metabolic consequences of, 108–11
Chemical carcinogenesis
DNA adducts and, 42–46
TCDD, 343–64
(See also Carcinogenesis, TCDD-induced carcinogenesis)
Chloroethylclonidine
α_1-adrenergic receptor subtypes and sensitivity to, 118–22, 124
Cholecystokinin-pancreozymin
C-terminal octapeptide of, 4–5
Cholinesterases, 281–312
acetylcholinesterase, 281–83, 285–312
butylcholinesterase, 282–83, 285, 287–88, 306–11
catalysis, 295–98
chimerae, 311
protein structure
gene organization and, 283, 285–88
site-specific mutagenesis analyses, 298–312
(See also Acetylcholinesterase, Butylcholinesterase, Serine hydrolase)
Chromomycin A3, 198
Chromosome 14
Alzheimer's disease and, 75
Chromosome 19
Alzheimer's disease and, 75
apolipoprotein E and, 75
Chromosome 21
Alzheimer's disease and, 74–75
β-amyloid precursor protein and
gene encoding, 75
Down's syndrome and, 74–75
Cocaine, 223–24
Collagenase, 13
Complement system
activation of, 19–35
alternate pathway, 21–22
classical pathway, 20–22
inhibitors of, 30–32
oxygen metabolite-mediated, 25
receptor-mediated mechanisms and, 19, 32–34
regulators of, 22–24
inflammatory response and, 19–35
membrane attack complex, 21–24, 27–31, 33–34
myocardial ischemia and, 18–19, 24–32
neutrophil activation and, 18–19, 24–35
regulatory proteins of, 22–24
reperfusion-induced injury and, 18–19, 24–35
Cyclosporin, 322, 325–26
[3-(Cystein-S-ye)methyl]indole (CYS), 103, 111
Cytochrome P-450
metabolic activation of 3-methylindole and, 96, 102, 105
Cytochrome P-450 isozymes
induction of, 351–56
Ah receptor and, 351
TCDD and, 351–56
metabolism of xenobiotics and, 251–68
regioselectivity of, 251–68
prediction of, 252–53
structure of binding site and, 262–68
site-directed mutagenesis of, 265–68
stereoselectivity of, 251–68
substrate specificity of, 251–68

D

Decay accelerating factor (DAF), 22–24, 31–32
Diacylglycerol, 177
Diaglycerol, 127–29
cis-Diamminedichloroplatinum (II) (cisDDP), 59
Dioxins
carcinogenicity of TCDD, 343–64
(See TCDD-induced carcinogenesis)
Dopamine, 224–25, 239
cocaine and, 224
Parkinson's disease and, 224
synaptic events and termination of, 225
Down's syndrome, 72–75, 81–82
Alzheimer's disease and, 72–75
β-amyloid deposition in, 72–73
β-amyloid precursor protein and, 75
chromosome 21 trisomy and, 74–75
neurofibrillary tangles and, 72–73
DNA adducts, 42–60, 138–39, 153–54, 162–63
aflatoxin B_1 and, 153, 162–63
enzyme-linked immunosorbent assay (ELISA) of, 42–43
high performance liquid chromatography (HPLC) of, 43
immunoaffinity chromatography of, 44
^{32}P-postlabeling assay of, 44–46
radioimmunoassay (RIA) of, 42–43
scanning fluorescence spectrophotometry (SFS) of, 44
ultrasensitive enzymatic radioimmunoassay (USERIA) of, 42–43
DNA topisomerases, 191–209
I, 193–200
drugs, 194–200
groove binders, 197–200
mechanism of catalysis, 193–200
II, 200–5
drugs, 203–5
intercalators, 203–5
mechanism of catalysis, 200–2
T4, 192–93
anticancer drugs, 192
mechanism of catalysis, 192
therapeutic targets, 192–93
Drug delivery
peptide
intravaginal, 337

nasal, 335–36
oral, 321–34
parenteral, 335
pulmonary, 337
rectal, 337
transdermal, 336–37
Drug metabolism
reactivity of substrate and, 252, 262
selectivity of substrate binding and, 252
Drug resistance
anticancer, 206–9

E

Ellipticine, 203
Enalapril, 14
Endopeptidase
neutral, 13
Endothelial-derived relaxing factor (EDRF), 175–77, 184–85
vasoconstriction and flow-initiated, 175, 177, 184–85
Energy metabolism
epinephrine and, 117
norepinephrine and, 117
Enzyme-linked immunosorbent assay (ELISA), 42–43
Epidemiology
molecular, 41–60
Epinephrine, 117
Estrogen receptor
TCDD-induced carcinogenesis and, 356–57
3,4-Ethylenedioxy-methamphetamine (MDMA)
serotonin transporters and, 224

F

Fosinopril, 14
Free radicals
3-methylindole toxicity and, 96, 98–100, 109–11

G

G protein–linked receptors
α_1-adrenergic subtypes, 117–30
GABA, 220–21, 225–28, 232–37, 242
permeation properties of, 232–37, 242
synaptic events and termination of, 225
Glutamate neurotransporters, 219, 221, 224, 232–37, 242
amyotrophic lateral sclerosis (ALS) and, 224
permeation properties of, 232–37, 242
synaptic events and termination of, 226
Glutathione (GSH), 99, 101–3, 111, 140
3-methylindole-glutathione adduct, 100
Glutathione S-transferase, 140, 143
Glycogen, 110
3-methylindole toxicity and, 100
Golgi complex
β-amyloid genesis and, 79–80
Groove binders, 197–200
GSH (See Glutathione)
Gut-associated lymphoid tissue (GALT), 324

H

Head trauma
Alzheimer's disease and risk of developing, 75, 82
Hemoglobin adducts, 46–48, 60
Hepatitis B virus, 55–56, 136, 138–39, 159
aflatoxins and, 55–56, 139, 159
synergy with, 139, 159
Hepatotoxicity, 135–36
High-performance liquid chromatography (HFLC), 43
Homologous restriction factor, 22–24, 31–32
5-Hydroxytryptamine (5-HT) (See Serotonin)

I

[^{131}I]Meta-iodobenzyl-guanidine, 224
Imidazole ring-opened aflatoxin B_1 (AFB_1)-DNA adduct, 43
Immunoaffinity chromatography, 44
Indole, 94
Indole-3-acetic acid (IAA), 92
Indolocarbazole, 200
Inflammatory response
complement system and, 19–35
membrane attack complex and, 21–22
myocardial, 18–19, 24–35
neutrophil-dependent, 18–19
Inositol-1,4,5-triphosphate (IP_3), 177
Intercalators, 203–5
Intercellular adhesion molecule-1 (ICAM-1), 33–34

K

Kunitz family of serine proteinase inhibitors, 77–78, 82–83
Kwashiorkor, 135

L

Lipid peroxidation, 100–1
Lung damage
3-methylindole and, 91–111
Lysinopril, 14

M

Macromolecular adducts, 48–60, 99–111
dosimetry of carcinogenesis and, 48–60
risk extrapolation, 53–54
excised, 48
3-methylindole-glutathione adduct, 99–100
Macromolecules
cellular, 100–11
methylindole binding to, 100–11
metabolic consequences to, 108–10
Mast cell chymase, 80
Membrane attack complex (MAC), 21–24, 27–31, 33–34
complement system activation and, 21–24, 27–30
myocardial ischemia and, 27–30
reperfusion injury and, 27–30
Membrane cofactor protein (MCP), 23, 31–32
Mendiones, 203
Metabolic activation
3-methylindole-toxicity and, 94–111
Metalloendopeptidase, 80
Methoxamine, 126–27
8-Methoxypsoralen (8-MOP) plus ultraviolet A light (PUVA), 58–59
N-Methyl-D-aspartate (NMDA) receptors, 227–28
3-Methylindole, 91–111
acute bovine pulmonary edema and emphysema and (ABPE) and, 91–92
binding to DNA, 104–8, 111
in bovine lung, 91–93
conversion from tryptophan diet and, 92–93
in human colon, 91
mechanism of toxicity of, 95–111

covalent binding to proteins and, 101–3
nucleic acid binding and, 104–8
metabolic activation of, 94–111
enzymatic requirement for, 95–97
reactive intermediate, 94–100
as prototype pneumotoxin, 92
3-Methylindole toxicity, 91–111
free radicals and, 96, 98–100, 109–11
glycogen and, 110
macromolecular targets, 100–11
lipid peroxidation and, 100–1
mechanism of, 95–111
metabolic activation and, 94–111
enzymatic requirement for, 95–97
mixed function oxidases and, 96–97
reactive intermediate and, 94–100
organ specificity, 94, 96–97
cytochrome P-450 and, 96
prostaglandin H synthase and, 96–97
phospholipid synthesis and, 109
typtophan to 3-methylindole conversion and, 92–93
5-Methyl-urapidil, 125
Mithramycin, 198
Mitoxantrone, 203
Mixed function oxidases
3-methylindole toxicity and, 96–100
Multicatalytic proteinase, 80
Muscle growth
α_1-adrenergic receptor subtypes and, 118
Mutagenesis
site-directed
cytochrome P-450 and, 265–68
Myocardial ischemia, 17–19, 24–35
complement system activation and, 18–19, 24–35
anaphylatoxins and, 24–26
inhibitors of, 30–32
membrane attack complex and, 27–30
opsonin formation and, 27
phagocytosis and, 27
oxygen paradox and, 17
reperfusion injury and, 17–19, 24–35
sources of oxygen metabolites and, 17, 25
superoxide dismutase and catalase and, 17

N

Nalidixic acid, 192
Nasal congestion
α_1-adrenergic receptor subtypes and, 118
Neurofibrillary tangles, 70–73, 80–83
Alzheimer's disease and, 70–73, 80–83
β-amyloid deposition and, 72–73, 80–83
Down's syndrome and, 72–73
Neurotransmitter transporters, 219–43
dopamine, 224, 239
drugs that target
abused, 223–24
therapeutic, 223–24
GABA, 220–21, 225–28, 232–37, 242
glutamate, 219, 221, 224, 240–41
norepinephrine, 224, 239
permeation pathway
localization of, 242–43
permeation properties of, 219, 228–43
electrophysiology studies of, 230–32
equilibrium studies of, 228–29
flux rate studies of, 229–30
GABA transport and, 232–37, 242
glutamate and, 240–42
ligand-binding studies of, 230
modulation of, 241–42
serotonin transport and, 237–40
vesicular, 241
releasing, 227–28
replentishing supply of, 226–27
choline and, 227
serotonin, 219, 224–25, 237–40
synaptic events and termination of, 225–26
Neutrophil-dependent inflammatory response, 18–19, 24–35
complement system and, 24–35
myocardial ischemia and, 18–19, 24–35
reperfusion injury and, 18–19, 24–35
Neutrophils, 18–19, 24–26, 29–30, 32–35
adherence of
effect of complement system on, 32–35
anaphylatoxins and, 19, 24–26, 29–30
(+)Niguldipine, 124–25
Nitric oxide
vascular smooth muscle tone and, 177, 181–83
NMDA receptors, 227–28
N-Nitrosamines
dosimetry of
carcinogenesis and, 50–52, 59–60
N-Nitrosodimethylamine (NDMA), 51
Nogalamycin, 198
Norepinephrine, 117, 124, 126, 224, 239
Novobiocin, 192
Nucleic acid binding, 104–8

O

Obsessive-compulsive disorder
serotonin and, 224
Opsonins, 27, 30
Oxygen paradox, 17
Oxygen toxicity
myocardial infarction and, 17, 25
Oxymetazoline, 125–27
Oxytocin, 1

P

p53 tumor suppression gene, 156–60
Paroxysmal nocturnal hemoglobinuria (PNH), 22–24
Peptide drug delivery, 321–37
alternate routes of, 334–37
intravaginal, 337
nasal, 335–36
parenteral, 335
pulmonary, 337
rectal, 337
transdermal, 336–37
oral, 321–34
absorption and, 322–24
brush border enzymes and, 330–31
carrier-mediated transport and, 326–28
cystolic enzymes and, 331
luminal enzymes and, 329–30
metabolism and, 323, 329–32

molecular weight and, 324–26
mucosal cell permeability and, 324–28
solubility and, 323–24
prodrugs, 332–33
Peptide synthesis
historical account of, 1–16
Peptidomimetic drugs, 321–37
alternate routes of delivery of, 334–37
oral systemic availability of, 321–34
prodrugs, 332–33
(See also Peptide drug delivery)
Phentololamine, 125
Phenylephrine, 126
a-Phenyl-tert-butyl-nitrone (PBN), 98
Phospholipid synthesis, 109–10
Platelet-activating factor, 26
Pneumotoxicosis
3-methylindole-induced, 91–111
mechanism of, 95–111
Polychlorinated dibenzofurans (PCDFs), 350
Polycyclic aromatic hydrocarbons (PAHs)
dosimetry of carcinogenesis and, 52, 57–58
Polyethylene glycols, 324
Prazosin, 124, 126
Prazobind, 126
Prodrugs, 332–33
Prolyendopeptidase, 80
Prostaglandin H synthetase (PHS), 96–101, 104, 108
Prostanoid, 175
Prostate function
α_1-adrenergic receptor subtypes and, 118
Protectin, 22–24
Protein adducts, 46–48, 60
albumin, 46–48
alkyl, 60
hemoglobin, 46–48, 60
Proteinase, 79–83
Alzheimer's disease and new therapeutic interventions for, 80–83
β-amyloid formation and, 79–83
calcium-activated neutral, 80
calcium-activated serine, 80
Kunitz family of serine proteinase inhibitors and, 77–78, 82–83
mast cell chymase, 80
prolyendopeptidase, 80

Q

Quinolone antibiotics, 192

R

Radioimmunoassay
of DNA adducts, 42–43
Ram seminal vesicles (RSV), 97
Regioselectivity
cytochrome P-450
hydroxylation of steroid hormones and, 253–56
prediction of, 252–53
Reperfusion injury, 17–35
cellular blood elements and, 18
complement system activation and, 18–19, 24–35
anaphylatoxins and, 24–26
membrane attack complex and, 27–30
opsonin formation and, 27–30
phagocytosis and, 27
molecular oxygen and, 17
myocardial, 17–35
neutrophil-dependent inflammatory response and, 18–19, 24–30
Reye's syndrome, 135

S

Scanning fluorence spectrophotometry (SFS), 44
Secretase, 78
Secretin, 3–5
Selectins, 32–33
Serine hydrolase
cholinesterases, 282–312
(See also Acetylcholinesterase, Butylcholinesterase, Cholinesterases)
Serotonin, 92, 219, 224, 237–40
antidepressants and, 224
cocaine and, 224
3,4-ethylenedioxy-methamphetamine (MDMA), 224
obsessive-compulsive disorder and, 224
permeation properties of, 237–40
synaptic events and termination of, 225
Serotonin receptor agonist, 125–26
5-methyl-urapidil, 125
Sincalide, 4
Site-specific mutagenesis
cholinesterases and, 298–312
Smooth endoplasmic reticulum, 95–97, 105, 108
cytochrome P-450 and, 96, 108
prostaglandin H synthetase and, 96–97, 105, 108
Smooth muscle
α_1-adrenergic receptor subtypes and, 118, 126
Smooth muscle tone
vascular, 173–86
drug influence on, 174, 180–86
flow-initiated vasoconstriction and dilation and, 173–75, 177–79
myogenic (stretch) dependent changes in, 173–74
sodium, 175–76, 178–79
Sodium
vascular smooth muscle tone and, 175–76, 178–79
Spiperone, 126
Stereoselectivity
cytochrome P-450, 251–68
Steroidogenesis
cytochrome P-450 and isozyme-specific regioselectivity and, 253–56
Substrate specificity
cytochrome P-450, 251–68

T

Tactins, 282–83
gliotactin, 282
neurotactin, 282
TCDD-induced carcinogenesis
Ah receptor and, 345, 347–47, 351–52, 355
biochemical responses in, 352–57
cytochrome P-450 isozyme induction and, 353–56
epidemiological studies
human, 357–61
estrogen receptor and, 356–57
initiation of, 351–52
mechanisms of, 347–51
risk assessment of, 348–49, 351
Teprotide, 5–8
Testosterone
hydroxylation of isozyme-specific regioselectivity of, 254–56
2,3,7,8-Tetrachloro-dibenzo-dioxin (TCDD) (See TCDD-induced carcinogenesis)
Tetrahydroaminoacridine (THA)

Alzheimer's disease and
treatment of, 72
side effects of, 72
Thermolysin, 13
Tobacco
tryptophan and, 91
Tryptophan, 91–93
conversion to 3-methylindole, 92–93
diet and, 92–93
Tumor suppressor genes
aflatoxins and inactivation of, 155–56

U

Ultrasensitive enzymatic radioimmunoassay (USERIA), 42–43

V

Vascular smooth muscle tone, 173–86
drug influence on, 174, 180–86
endothelium-dependent response to flow, 177
endothelium-independent response to flow, 177–79
flow-dependent changes in, 173–86
norepinephrine and, 184–85
pharmacological implications of, 184–86
techniques for study of, 175–76
vascular endothelial cells and, 181–83
flow-initiated vasoconstriction and dilation and, 173–86
myogenic (stretch) dependent changes in, 173–74
Vasoconstriction
flow-initiated, 173–75, 177–79
extracellular Na^+ and, 178–79
Vasodilation
flow-initiated, 173–75, 177–79
extracellular Na^+ and, 178–79
Vasopressin, 1, 334
1-desamino-8-D-arginine, 334
lysine, 334
Vinblastine, 206
Vitronectin, 23
VM-26, 203
VP-16, 203

W

Warfarin, 257
WB 4101, 125

X

Xenobiotics
metabolism of
cytochrome P-450 mediated, 251–68
regioselective, 251, 256–57, 262

Z

Zofenopril, 14